# Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

> **NCT04727996** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 43 (actual)

## Conditions studied

- Advanced Biliary Tract Cancer

## Interventions

- **DRUG:** Sitravatinib
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT04727996
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2023-07-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04727996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04727996, "Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04727996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*